- Home
- ADIL vs INAB Comparison
ADIL vs INAB Comparison
Compare ADIL & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- INAB
- Stock Information
- Founded
- ADIL 2010
- INAB 2016
- Country
- ADIL United States
- INAB United States
- Employees
- ADIL N/A
- INAB N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- INAB Health Care
- Exchange
- ADIL Nasdaq
- INAB Nasdaq
- Market Cap
- ADIL 7.6M
- INAB 9.1M
- IPO Year
- ADIL 2018
- INAB 2021
- Fundamental
- Price
- ADIL $0.35
- INAB $2.00
- Analyst Decision
- ADIL Strong Buy
- INAB Strong Buy
- Analyst Count
- ADIL 1
- INAB 2
- Target Price
- ADIL $8.00
- INAB $108.00
- AVG Volume (30 Days)
- ADIL 562.1K
- INAB 45.9K
- Earning Date
- ADIL 11-12-2025
- INAB 11-11-2025
- Dividend Yield
- ADIL N/A
- INAB N/A
- EPS Growth
- ADIL N/A
- INAB N/A
- EPS
- ADIL N/A
- INAB N/A
- Revenue
- ADIL N/A
- INAB N/A
- Revenue This Year
- ADIL N/A
- INAB N/A
- Revenue Next Year
- ADIL N/A
- INAB N/A
- P/E Ratio
- ADIL N/A
- INAB N/A
- Revenue Growth
- ADIL N/A
- INAB N/A
- 52 Week Low
- ADIL $0.22
- INAB $1.91
- 52 Week High
- ADIL $1.30
- INAB $16.70
- Technical
- Relative Strength Index (RSI)
- ADIL 36.98
- INAB 39.35
- Support Level
- ADIL $0.36
- INAB $1.91
- Resistance Level
- ADIL $0.38
- INAB $2.20
- Average True Range (ATR)
- ADIL 0.02
- INAB 0.11
- MACD
- ADIL 0.00
- INAB -0.01
- Stochastic Oscillator
- ADIL 14.00
- INAB 23.08
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.